Autologous Bone Marrow Transplantation

References

• Cavins J. A., Kasakura S., Thomas E. D., et al. Recovery of lethally irradiated dogs following infusion of autologous marrow stored at low temperatures in dimethylsulfoxide. Blood 1962; 20: 730–4
   PubMed Web of Science ®Google Scholar
• English D., Lamberson R., Graves V., et al. Semi-automated processing of bone marrow for transplantation. Transfusion 1989; 29: 12–6
   PubMedGoogle Scholar
• Stiff P. J., KoesteT AR, Weidner M. K., et al. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled rate freezing. Blood 1987; 70: 974–8
   PubMed Web of Science ®Google Scholar
• Broxmeyer H. E., Gluckman E., Auerbach A., et al. Human umbilical cord blood: a clinically useful source of transplantable hematopoietic stem/progenitor cells. Int J Cell Cloning 1990; 8(1)76–91
   PubMedGoogle Scholar
• Gluckman E., Broxmeyer H. E., Auerbach A. D., et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of blood from an HLA-identical sibling. N Engl J Med 1989; 321(17)1174–8
   PubMed Web of Science ®Google Scholar
• Lasky L. C. Hematopoietic reconstitution using progenitors recovered from blood. Transfusion 1989; 29: 552
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J. O., Smith D. M., et al. High dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260
   PubMed Web of Science ®Google Scholar
• Richman C. M., Weiner RS, Yankee R. A. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031–9
   PubMed Web of Science ®Google Scholar
• Elias A. D., Ayash L., Anderson K. C., et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony stimulating factor for hematologic support after high dose intensification for breast cancer. Blood 1992; 79: 3036–44
   PubMed Web of Science ®Google Scholar
• Gianni A. M., Siena S., Bregni M., et al. Granulocyte macrophage colony stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet. 1989; 2: 580–5
   PubMed Web of Science ®Google Scholar
• Haas R., Ho A. D., Bredthauer U., et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony stimulating factor. Exp Hematol 1990; 18: 94
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Begley C. G., Juttner C. A., et al. Effect of peripheral blood progenitor cells mobilized by filgramstim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992; 339: 640–4
   PubMed Web of Science ®Google Scholar
• Siena S., Bregni M., Brando B., et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77: 400–9
   PubMed Web of Science ®Google Scholar
• Frei E., Canellos G. P. Dose a critical factor in cancer therapy. Am J Med 1980; 69: 585–94
   PubMed Web of Science ®Google Scholar
• Herzig G. Autologous marrow transplantation in cancer therapy. Exp Hematol. 1981; 9: 1–24
   PubMedGoogle Scholar
• Applebaum F. R., Buckner C. D. Overview of the clinical relevance of autologous bone marrow transplantation. Clin Haematol 1986; IS: 1–18
   Google Scholar
• Peters W. P., Shpall E. J., Jones R. B., et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988; 6: 1368–76
   PubMed Web of Science ®Google Scholar
• Williams S. F., Gilewski T., Mick R., Bitran J. D. High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743–7
   PubMed Web of Science ®Google Scholar
• Antman K., Ayash L., Elias A., et al. A phase JJ study of high dose cyclophosphamide, thiotepa and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102–10
   PubMed Web of Science ®Google Scholar
• Dunphy F. R., Spitzer G., Buzdar A. U., et al. Treatment of estrogen receptor-negative or hormon-ally refractory breast cancer with double high dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–16
   PubMed Web of Science ®Google Scholar
• Jones R. B., Shpall E. J., Shogan J., et al. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431–6
   PubMed Web of Science ®Google Scholar
• Vincent M. D., Trevor J., Powles R., et al. Late intensification with high dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 1988; 21: 255–60
   PubMed Web of Science ®Google Scholar
• Jones S. E., Moon T. E., Bonadonna G., et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 1987; 10: 387–95
   PubMed Web of Science ®Google Scholar
• Fisher B., Bauer B., Wickerham D. L., et al. Relation of number of positive axillary lymph nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 1982; 52: 1551–7
   Google Scholar
• Hortobagyi G. N., Ames F. C., Buzdar A. U., et al. Management of stage HI primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62: 2507–16
   PubMed Web of Science ®Google Scholar
• Roouesse J., Friedman S, Sarrazin D. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol. 1986; 4: 1765–71
   PubMedGoogle Scholar
• Peter W. P., Ross M., Vredenburgh J. J., et al. High dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol 1993; 11: 1132–43
   PubMedGoogle Scholar
• Mulder N. H., Mulder POM, Sleijfer D. T., et al. Induction chemotherapy and intensification with autologous bone marrow reinfusion in patients with locally advanced and disseminated breast cancer. Eur J Cancer. 1993; 29A: 668–71
   PubMed Web of Science ®Google Scholar
• Broun E. R., Sledge G. W., Loesch D., et al. Two cycles of high dose chemotherapy with autologous bone marrow rescue (ABMR) as initial therapy for stage JJIB breast cancer. Accepted for presentation at San Antonio Breast Symposium. 1993
   Google Scholar
• Richardson G. S., Scully R. E., Najamosa N., et al. Common epithelial cancer of the ovary. N Engl J Med 1985; 312: 412–24
   Google Scholar
• Sutton G. P., Stehman F. B., Ehrlich C. E., et al. Seven year follow-up of patients receiving cisplatin, adriamycin and cyclophosphamide (PAQ chemotherapy for stage III and IV epithelial ovarian cancer. Proc Am Soc Clin Oncol. 1986; 5: 120
   Google Scholar
• Ozols R. F., Young R. C. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222–32
   PubMed Web of Science ®Google Scholar
• McGuire W. P., Rowinsky E. K., Rosenshein N. B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann IntMed 1989; 111: 273–9
   PubMed Web of Science ®Google Scholar
• Levin L., Hryniuk W. M. Dose intensity analyses of chemotherapy regimens in ovarian cancer. J Clin Oncol. 1987; 5: 756–67
   PubMed Web of Science ®Google Scholar
• Bruchner H., Wallach R. High dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1981; 12: 64–7
   PubMedGoogle Scholar
• Ozols R., Osstchega Y., Myeres C., et al. High dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 1985; 3: 1246–50
   PubMed Web of Science ®Google Scholar
• Nores J. M., Dalayeun J., Otmezguine Y., et al. Treatment of advanced cancer of the ovary using intensive chemotherapy with autograft of bone marrow. From a case, discussion and review of the literature. Rev Fr Gynecol Obstet. 1987; 82(5)355–9
   PubMedGoogle Scholar
• Vriesendorp R., Aalders J. G., Sleijfer D. T., et al. Effective high dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984; 17: 271–6
   PubMed Web of Science ®Google Scholar
• Postmus P. E., DeVries E. G., deVries-Hospers H. G., et al. Cyclophosphamide and VP 16–213 with autologous bone marrow transplantation. A dose escalation study. Eur J Can Clin Oncol 1984; 20: 777–82
   PubMedGoogle Scholar
• Mulder POM, Sleijfer D. T., Willemse PHB, et al. High dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989; 49: 4654–8
   PubMed Web of Science ®Google Scholar
• Mulder POM, Willemse PHB, Azalders J. G., et al. High dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Can Clin Oncol 1989; 25: 645–9
   PubMedGoogle Scholar
• Viens P., Maraninichi D., Legros M., et al. High dose melphalan and autologous bone marrow rescue in advanced ovarian epithelial carcinoma: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant. 1990; 5: 227–33
   PubMed Web of Science ®Google Scholar
• Legros M., Fleury J., Cure H., et al. High dose chemotherapy and autologous bone marrow transplant in 31 advanced ovarian cancers: long term results. Proc Am Soc Clin Oncol 1992; 11: 222
   Google Scholar
• Schpall E. J., Clarke-Pearson D., Soper J. T., et al. High dose alkylating agent chemotherapy with autologous bone marrow support in patients with Stage HI/TV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386–91
   PubMedGoogle Scholar
• Stiff P., Bayer R., Sosman J., et al. High dose mitoxantrone, carboplatin, and cyclophosphamide with marrow rescue: effective salvage therapy for ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 256
   Google Scholar
• Lotz J. P., Machover D., Bellaiche A., et al. Tandem high dose (HD) chemotherapy with VM-26, ifosfamide and carboplatin with autologous bone marrow transplantation for patients with stage HJc-rV ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 257
   Google Scholar
• Jagannath S., Armitage J. O., Dicke K. A., et al (1989) Timing of high dose CBV and autologous bone marrow transplantation in the management of relapsed or refractory Hodgkins disease. Autologous bone marrow transplantation.Proceedings of the Fourth International Symposium. 1989, K. A. Dicke, G. Spitzer, S. Jagannath, M. J. Evinger-Hodges. University of Texas MD Anderson Cancer Center, Houston, 275
   Google Scholar
• Harker W. G., Kushlan P, Rosenberg S. A. Combination chemotherapy for advanced Hodgkins disease after failure of MOPP, ABVD and B-CAVe. Ann Intern Med 1984; 101: 440–6
   PubMed Web of Science ®Google Scholar
• Tannir N., Hagemeister F., Velasquez W., et al. Long term follow-up with ABDIC salvage chemotherapy of MOOPP resistant Hodgkins disease. J Clin Oncol. 1983; 1: 432–9
   PubMed Web of Science ®Google Scholar
• Desch C. E., Lasala M. R., Smith T. J., et al. The optimal timing of autologous bone marrow transplantation in Hodgkins disease patients after a chemotherapy relapse. J Clin Oncol 1992; 10: 200–9
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkins disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210–8
   PubMed Web of Science ®Google Scholar
• Reece D. E., Barnett M. J., Connors J. M., et al. Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkins disease. J Clin Oncol. 1991; 9: 1871–9
   PubMed Web of Science ®Google Scholar
• Jagannath S., Dicke K. A., Armitage J. O., et al. High dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkins disease. Ann Intern Med 1986; 104: 163–8
   PubMed Web of Science ®Google Scholar
• Carella A. M., Conigu A. M., Gaozza E., et al. High dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Study Group report. J Clin Oncol 1988; 6: 1411–6
   PubMed Web of Science ®Google Scholar
• Philip T., Dumont J., Teillet F., et al. High dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkins disease. Br J Cancer 1986; 53: 737–42
   PubMed Web of Science ®Google Scholar
• Kessinger A., Bierman P. J., Vose J. M., et al. High dose cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkins disease. Blood 1991; 77: 2322–5
   PubMed Web of Science ®Google Scholar
• Jones R. J., Piantadosi S., Mann R. B., et al. High dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkins disease. J Clin Oncol. 1990; 8: 527–37
   PubMed Web of Science ®Google Scholar
• Surbone A., Armitage JO, Gale R. P. Autotransplantation in lymphoma: better therapy or healthier patients%. Ann Intern Med 1991; 12: 1059–60
   Google Scholar
• Bierman P. J., Anderson J., Vose J., et al. High dose chemotherapy with autologous hematopoietic rescue for Hodgkins disease (HD) following first relapse after chemotherapy. Proc Am Soc Clin Oncol 1993; 12: 366
   Google Scholar
• Shipp M., Harrington D., Anderson J., et al. Development of a predictive model for aggressive lymphoma: the International NHL prognostic factors project. Proc Am Soc Clin Oncol 1992; 11: 319
   Google Scholar
• Zulian G. B., Selby P., Milan S., et al. High dose melphalan, BCNU, and etoposide with autologous bone marrow transplantation for Hodgkins disease. Br J Cancer 1989; 59: 631–5
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Linen D. C., Singer CRJ, et al. Successful treatment of refractory Hodgkins disease by high dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–4
   PubMed Web of Science ®Google Scholar
• Pecego R., Hill R., Applebaum F. R., et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986; 42: 515–7
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Wolff S. N., Herzig R. H., et al. Treatment of progressive Hodgkins disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086–92
   PubMed Web of Science ®Google Scholar
• Bierman P. J., Vose JM, Armitage J. O. Chemotherapy sensitivity predicts a better outcome with high dose therapy and autotransplantation in Hodgkins disease. Proc Am Soc Clin Oncol. 1990; 9: 259
   Google Scholar
• Philip T., Armitage J. O., Spitzer G., et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate or high grade nonHodgkins lymphoma. N Engl J Med 1987; 316: 1493–8
   PubMed Web of Science ®Google Scholar
• Bosly A., Coiffier B., Gisselbrecht C., et al. Bone marrow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the NHL-84 regimen. J Clin Oncol 1992; 10: 1615–23
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Shank B., Black P., et al. Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol. 1988; 6: 1303–13
   PubMed Web of Science ®Google Scholar
• Verdonck L. F., Dekker A. W., deGast G. C., et al. Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992; 10: 644–6
   PubMed Web of Science ®Google Scholar
• Nademanee A., Schmidt G. M., O'Donnel M. R., et al. High dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor risk aggressive lymphoma: a pilot study. Blood. 1992; 5: 1130–4
   Google Scholar
• Santini G., Coser P., Chisesi T., et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. A pilot study of the nonHodgkins Lymphoma Co-Operative Study Group. Br J Cancer. 1989; 4: 399–404
   Google Scholar
• Applebaum F. R., Sullivan K. M., Buckner C. D., et al. Treatment of malignant lymphoma in 100 patients with chemotherapy total body irradiation and marrow transplantation. J Clin Oncol. 1987; 5: 1340–7
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Herzig R. H., Lazarus H. M., et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation and transplantation of cryopreserved autologous marrow. N Engl J Med 1984; 310: 1557–61
   PubMed Web of Science ®Google Scholar
• Takvorian T., Canellos G. P., Ritz J., et al. Prolonged disease free survival after autologous bone marrow transplantation in patients with nonHodgkins lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499–1506
   PubMed Web of Science ®Google Scholar
• Petersen F. B., Applebaum F. R., Bigelow C. L., et al. High dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Br J Cancer. 1989; 4: 483–8
   Google Scholar
• Blume K. G., Forman S. J., O'Donnell M. R., et al. Total body irradiation and high dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015–20
   PubMed Web of Science ®Google Scholar
• Petersen F. B., Buckner C. D., Appelbaum F. R., et al. Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematologic malignancies: a phase I study. Br J Cancer 1992; 10: 83–8
   Google Scholar
• Armitage J. O., Gingrich R. D., Klassen L. W., et al. Trial of high dose cytarabine, cyclophosphamide, total body irradiation and autologous marrow transplantation for refractory lymphoma. Cancer Treat Rep 1986; 70: 871–5
   PubMedGoogle Scholar
• Jagannath S., Armitage J. O., Dicke K. A., et al. Prognostic factors for response and survival after high dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkins. J Clin Oncol. 1989; 7: 179
   PubMed Web of Science ®Google Scholar
• Wheeler C., Strawderman M., Ayash L., et al. Prognostic factors for treatment outcome in autotransplantation of intermediate grade and high grade nonHodgkins lymphoma with cyclophosphamide, carmustine and etoposide. J Clin Oncol 1993; 11: 1085–91
   PubMed Web of Science ®Google Scholar
• Wheeler C., Antin J. H., Churchill H., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkins disease and nonHodgkins lymphoma: a dose finding study. J Clin Oncol. 1990; 8: 648–56
   PubMed Web of Science ®Google Scholar
• Portlock C. S. “Good risk” non Hodgkin's lymphomas: approaches in management. Semin Hematol 1983; 20: 25
   PubMed Web of Science ®Google Scholar
• Gallagher C. J., Gregory W. M., Jones A. E., et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986; 4: 1470–6
   PubMed Web of Science ®Google Scholar
• Hurd D. D., LeBien T. W., Lasky L. C., et al. Autologous bone marrow transplantation in nonHodgkin's lymphoma: monoclonal antibodies plus complement for. ex vivo marrow treatment. Am J Med. 1988; 85: 829–34
   PubMed Web of Science ®Google Scholar
• Schouten H. C., Bierman P. J., Vaughn W. P., et al. Autologous bone marrow transplantation in follicular nonHodgkin's lymphoma before and after histological transformation. Blood 1989; 74: 2579–85
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Ritz J., Neuberg D., et al. Autologous bone marrow transplantation in 69 patients with a history of low grade B-cell nonHodgkin's lymphoma. Blood 1991; 77: 2524–30
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Price CGA, Arnott S. J., et al (1991) Ablative therapy with autologous bone marrow transplantation as consolidation of remission in patients with follicular lymphoma. Autologous bone marrow transplantation V, proceedings of the fifth international symposium. 1991, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger. University of Nebraska Medical Press, Omaha, 465
   Google Scholar
• Nichols C. R., Tricot G., Williams S. D., et al. Dose intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989; 7(7)932–9
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Storb R., Clift R. A., et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832–43, 895–902
   PubMed Web of Science ®Google Scholar
• Nichols C. R., Andersen J., Wolff S. N., et al. High dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer, an Eastern Cooperative Group Protocol. J Clin Oncol 1992; 10: 558–63
   PubMed Web of Science ®Google Scholar
• Broun E. R., Nichols C. R., Einhorn L. H., et al. Salvage therapy with high dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 1991; 68: 1513–5
   PubMedGoogle Scholar
• Pico J. L., Droz J-P, Ostronoff M., et al. High dose chemotherapy and autologous bone marrow transplantation for poor diagnosis non-seminatous germ cell tumors. Autologous bone marrow transplantation: proc of the fourth international symposium. 1989; 469–476
   Google Scholar
• Loehrer P. J., Einhom LH, Williams S. D. Salvage therapy for refractory germ cell tumors with VP-16 plus ifosfamide plus cisplatin. J Clin Oncol. 1986; 4: 528–39
   PubMed Web of Science ®Google Scholar
• Loehrer P. J., Lauer R., Roth B. J., et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Int Med 1988; 109(7)540–46
   PubMed Web of Science ®Google Scholar
• Broun E. R., Nichols C., Tricot G., et al. High dose carboplatin/VP-16 plus ifosfamide with autologous bone marrow support in the treatment of refractory germ cell rumors. Bone Marrow Transplant. 1991; 7: 53–6
   PubMed Web of Science ®Google Scholar
• Broun E. R., Nichols C. R., Kneebone P., et al. Long term outcome of patients with relapsed and refractory germ cell tumors treated with high dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124–8
   PubMed Web of Science ®Google Scholar
• Elias A. D., Ayash L. J., Eder J. P., et al. A phase I study of high dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol 1991; 9: 320–7
   PubMed Web of Science ®Google Scholar
• Siebert W., Beyer J., Weisbach V., et al. High dose carboplatin (C), etoposide (E), and ifosfamide (I) with autologous stem cell rescue (ASCR) for relapsed and refractory germ cell tumors. Proc Am Soc Clin Oncol 1991; 10: 163
   Google Scholar
• Broun E. R., Nichols C. R., Turns M., et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994; 73: 1716–20
   PubMedGoogle Scholar
• Motzer R. J., Guilati S. C., Crown J. P., et al. High dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: early intervention is better tolerated. Cancer 1992; 69: 550–3
   PubMed Web of Science ®Google Scholar
• Weisdorf D. J., Nesbit M. E., Ramsay NKC, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft vs host disease. J Clin Oncol. 1987; 5: 1348–55
   PubMed Web of Science ®Google Scholar
• Rill D. R., Moen R., Buschle M., et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992; 79: 2694–2700
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–6
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Douay L., Laporte J. P., et al. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. Blood 1986; 67: 1367–76
   PubMed Web of Science ®Google Scholar
• Rizzoli V., Mangoni L., Carella A. M., et al. Drug-mediated marrow purging: maphosphamide in adult acute leukemia in remission. Bone Marrow Transplant. 1989; 4(1)190
   PubMedGoogle Scholar
• Uckun F. M., Kersey J. H., Vallera D. A., et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydro-peroxycyclophosphamide for marrow purging. Blood 1990; 76: 1723–33
   PubMed Web of Science ®Google Scholar
• Kaizer H., Stuart R. K., Brookmeyer R., et al. Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood 1985; 65: 1504–10
   PubMed Web of Science ®Google Scholar
• Yeager A. M., Kaizer H., Santos G. W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141–7
   PubMed Web of Science ®Google Scholar
• Gulati S., Acaba L., Yahalom J., et al. Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow. Bone Marrow Transplant 1992; 10: 129–34
   PubMedGoogle Scholar
• LaPorte JPH, Douay L., Lopez M., et al. 134 patients with acute leukemia autografted (ABMT) using mafosfamide purged marrow: a ten year single institution experience. Blood 1993; 82(1)82
   Google Scholar
• Ball E. D., Mills L. E., Hurd D., et al. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody purged bone marrow. Prog Clin Biol Res 1992; 377: 97–111
   PubMedGoogle Scholar
• Ramsey NKC, LeBien T., Nesbit M, et al. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 1985; 66: 508–13
   PubMedGoogle Scholar
• Sallan S. E., Niemeyer C. M., Billet A. L., et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989; 7: 1–8
   PubMedGoogle Scholar
• Preijers FWMB, DeWitte T., Wessels JMC, et al. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WTl-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152–8
   PubMed Web of Science ®Google Scholar
• Strong R., Uckun F., Youie R., et al. Use of multiple T-cell directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood 1985; 66: 627–35
   PubMed Web of Science ®Google Scholar
• Kiesel S., Haas R., Moldenhauer G., et al. Removal of cells for a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytolysis. Leuk Res 1987; 11: 1119–25
   PubMed Web of Science ®Google Scholar
• Bast R., DeFabntiis P., Lipton J., et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Kersey J., Haake R., et al. Autologous bone marrow transplantation in high risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 79: 1094–1104
   PubMed Web of Science ®Google Scholar
• Beelen D. W., Quabeck K., Graeven U., et al. Acute toxicity and first clinical results of intensive post induction therapy using a modified bisulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 1989; 74: 1507–16
   PubMed Web of Science ®Google Scholar
• Meloni G., DeFabntiis P., Petti M. C., et al. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282–5
   PubMed Web of Science ®Google Scholar
• Chopra R., Goldstone A. H., McMillan A. K., et al. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using bisulfan. J cyclophosphamide and unpurged marrow: the British Autograft Group experience. J Clin Oncol 1991; 1840–7
   Google Scholar
• Woods W., Ramsay NKC, Weisdorf D. J., et al. Bone marrow transplantation for acute lymphoblastic leukemia utilizing total body irradiation followed by high doses of cytosine arabino-side. Bone Marrow Transplant. 1990; 6: 9–16
   PubMed Web of Science ®Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukemia. N EnglJMed 1987; 317: 461–7
   PubMed Web of Science ®Google Scholar
• Ramsay N., LeBien T., Weisdorf D., et al. Autologous BMT for patients with acute lymphoblastic leukemia. Bone marrow transplantation: current controversies, RPCR Gale. Alan R. Liss, New York 1989; 57
   Google Scholar
• Cahn J. Y., Bordignoni P., Souillet G., et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: a cooperative study of 62 patients. Bone Marrow Transplant. 1991; 7: 1–4
   PubMed Web of Science ®Google Scholar
• Schroeder H., Pinkerton C., Powles R., et al. High dose melphalan and total body irradiation with autologous marrow rescue in chUdhood acute lymphoblastic leukemia after relapse. Bone Marrow Transplant. 1991; 7: 11–5
   PubMedGoogle Scholar
• Pico J., Hartmann O., Maraninchi D., et al. Modified chemotherapy with carmustine, cytarabine, cyclophosphamide and 6-thioguanine (B ACT) and autologous bone marrow transplantation in 24 poor risk patients with acute lymphoblastic leukemia. J Natl Cancer Inst 1986; 76: 1289–93
   PubMedGoogle Scholar
• Ritz J., Ramsey N. K., Kersey J. H. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone marrow transplantation, SJBK Forman, E. D. Thomas. Blackwell Scientific, Boston 1994; 731–42
   Google Scholar
• Billett A. L., Kornmehl E., Tarbell N. J., et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 1993; 81: 1651–7
   PubMed Web of Science ®Google Scholar
• Soiffer R. J., Roy D. C., Gonin R., et al. Monoclonal antibody purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk for subsequent relapse. Bone Marrow Transplant, (in press)
   Google Scholar
• Rosenfeld C., Shadduck R. K., Przepiorka D., et al. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for acute nonlymphocytic leukemia in late remission or early relapse. Blood 1989; 74: 1159–64
   PubMedGoogle Scholar
• Lambertenghi, Deliliers G., Delia Volpe A., Annaloro C., et al. Long term disease free survival in AML patients after autologous bone marrow transplantation. Blood 1993; 82(1)166, a
   Google Scholar
• Tarantolo S. R., Bishop M. R., Spinolo J. A., et al. Super-consolidation with high dose chemotherapy and unpurged autologous bone marrow transplant for AML in first remission. Blood 1993; 82(1)168, a
   Google Scholar
• Zittoun R., Mandelli F., Willemze R., et al. Prospective phase HI study of autologous bone marrow transplantation (ABMT) v short intensive chemotherapy (IC) v allogeneic bone marrow transplantation (ALLO-BMT) during first complete remission (CR) of acute myelogenous leukemia (AML). Results of the EORTC-GIMEMA AML 8 A trial. Blood 1993; 82(1)85, a
   Google Scholar
• Mbidde E. K., Wolff S. N., Fay J. W., et al. Intensive BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 1988; 58: 779–92
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Wolff S. N., Fay JW, et al. Intensive BCNU chemotherapy and autologous bone marrow transplantation for malignant gliomas. J Clin Oncol. 1986; 4: 639–45
   PubMed Web of Science ®Google Scholar
• Saarinen U. M., Hovi L, Makipernaa A. High dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma. J Neurooncol. 1990; 9: 57–61
   PubMed Web of Science ®Google Scholar
• Giannone L., Wolff S. N. Phase U treatment of central nervous system gliomas with high dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 1987; 71: 759–61
   PubMedGoogle Scholar
• Wolff S. N., Phillips GL, Herzig G. P. High dose BCNU with autologous bone marrow transplantation for the adjuvant treatment of high grade gliomas of the central nervous system. Cancer Treat Rep 1987; 71: 183–5
   PubMedGoogle Scholar
• Allen J. C., Helson L. High dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 1981; 55: 749–56
   PubMed Web of Science ®Google Scholar
• Johnson D. B., Thompson J., Crowin J. A., et al. Prolongation of survival for high grade malignant gliomas with adjuvant high dose BCNU and autologous bone marrow transplantation. J Clin Oncol. 1987; 5: 783–9
   PubMed Web of Science ®Google Scholar
• Bell A. J., Figes A., Oscier D. G., et al. Peripheral blood stem cell autografting. Lancet. 1986; 1: 1027
   PubMedGoogle Scholar
• Kessinger A., Armitage J. O., Landmark J. D., et al. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986; 14: 192–6
   PubMed Web of Science ®Google Scholar
• Kessinger A., Armitage J. O., Landmark J. D., et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723–7
   PubMed Web of Science ®Google Scholar
• To L. B., Roberts M. M., Haylock D. N., et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants; autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992; 9: 277–84
   PubMed Web of Science ®Google Scholar
• Thomas E. D., Storb R. Technique for human marrow grafting. Blood 1970; 36: 507–15
   PubMed Web of Science ®Google Scholar
• Jansen J. Processing of bone marrow for allogeneic transplantation. Processing of bone marrow for transplantation, R. A. Sacher, L. J. McCarthy, Sibinga C. T. Smit. VA: American Association of Blood Banks, Arlington 1990; 19–39
   Google Scholar
• Gorin N. C. Collection, manipulation and freezing of haemopoietic stem cells. Clinics in haematology: autologous bone marrow transplantation, AH Gold-Stone. WB Saunders, Philadelphia 1986
   Google Scholar
• Slowman S., Danielson C., Graves V., et al. Administration of GM-/G-CSF prior to bone marrow harvest increases collection of CD34+ cells, (in press)
   Google Scholar
• AABB Standards Committee. AABB standards for blood banks and transfusion services.15th ed., FK Widmann. American Association of Blood Banks, Bethesda, MD 1993
   Google Scholar
• Reich L. M., Self S. Z., Mayer K. A simple technique to overcome ABH incompatibility in bone marrow transplants. Transfusion 1980; 20: 640
   Web of Science ®Google Scholar
• Linch D. C., Knott L. J., Patterson K. G., et al. Bone marrow processing and cryopreservation. J Clin Pathol 1982; 35: 186–90
   PubMed Web of Science ®Google Scholar
• Ma DDF, Biggs J. C. Comparison of two methods for concentrating stem cells for cryopreservation and transplantation. Transfusion 1982; 22: 217–9
   PubMedGoogle Scholar
• Dinsmore R. E., Reich L. M., Kapoor N. ABH incompatible bone marrow transplantation: removal of erythrocytes by starch sedimentation. Br J Haematol 1983; 54: 441–9
   PubMed Web of Science ®Google Scholar
• Lasky L. C., Warkentin P. I., Kersey J. H., et al. Hemotherapy in patients undergoing blood group incompatible bone marrow transplantation. Transfusion 1983; 23: 277–85
   PubMed Web of Science ®Google Scholar
• Ho W. G., Champlin R. E., Feig S. A., et al. Transplantation of ABH incompatible bone marrow: gravity sedimentation of donor marrow. Br J Haematol 1984; 57: 155–62
   PubMedGoogle Scholar
• Ramsay N., LeBien T., Nesbit M., et al. Autologous bone marrow transplantation for patients with acute lymphoblastic leukemia in second or subsequent remission: results of bone marrow treated with monoclonal antibodies BA-1, BA-2, and BA-3 plus complement. Blood 1985; 66: 508–13
   PubMed Web of Science ®Google Scholar
• Warkentin P. I., Hilden J. M., Kersey J. H., et al. Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch. Vox Sang 1985; 48: 89–104
   PubMed Web of Science ®Google Scholar
• Wells J. R., Sullivan A, Cline M. J. A technique for the separation and cryopreservation of myeloid stem cells from human bone marrow. Cryobiology 1979; 18: 201–10
   Google Scholar
• Carciero R., Valeri C. R. Isolation of mononuclear leukocytes in a plastic bag system using ficoll-hypaque. Vox Sang 1985; 49: 373–80
   PubMedGoogle Scholar
• Wiesneth M., Hertenstein B., Koerner K., et al. Concentration of bone marrow mononuclear cells for in vitro treatment and ABO-incompatible transplantation: a rapid and reproducible procedure using the Haemonetics V50® cell separator. Beitr Infusionsther 1988; 21: 340–5
   PubMedGoogle Scholar
• Anderson N. A., Godwin V., Gunstone M. J., et al. Bone marrow processing using the Haemonetics V50 cell separator. Br J Haematol 1989; 71(1)44
   Google Scholar
• Law P., Dooley D. C., Alsop P., et al. Density gradient isolation of peripheral blood mononuclear cells using a blood cell processor. Transfusion 1988; 28: 145–50
   PubMed Web of Science ®Google Scholar
• Gilmore MJML, Prentice H. G., Blacklock DDF, et al. A technique for rapid isolation of bone marrow mononuclear cells using ficoll-metrizoate and the IBM 2991 blood cell processor. Br J Haematol 1982; 50: 619–26
   PubMed Web of Science ®Google Scholar
• Gilmore MJML, Prentice H. G., Coningham R. E., et al. A technique for die concentration of nucleated bone marrow cells for in vitro manipulation or cryopreservation using the IBM blood cell processor. Vox Sang 1983; 45: 294–302
   PubMed Web of Science ®Google Scholar
• Ritchey B., Henry S., Forman S. J., et al. A new technique using differential centrifugation of bone marrow for ABO incompatible transplants. Transplantation 1983; 35: 638–9
   PubMedGoogle Scholar
• Sniecinski I., Henry S., Ritchey B., et al. Erythrocyte depletion of ABO-incompatible bone marrow. J Clin Apheresis. 1985; 2: 231–4
   PubMedGoogle Scholar
• Jin N-R, Hill R., Segal G., et al. Preparation of red-blood-cell-depleted marrow for ABO-incompatible marrow transplantation by density-gradient separation using the IBM 2991 blood cell processor. Exp Hematol 1987; 15: 93–8
   PubMedGoogle Scholar
• Faradji A., Andreu B., Pillier-Lorette C., et al. Separation of mononuclear bone marrow cells using the Cobe 2997 blood cell separator. Vox Sang 1988; 55: 133–8
   PubMedGoogle Scholar
• Dragani A., Angelini A., Iacone A., et al. Comparison of five methods for concentrating progenitor cells in human marrow transplantation. Blut 1990; 60: 278–81
   PubMedGoogle Scholar
• Baker P. K., Rhodes EGH, Duguid JKM. Continuous flow cell separator use for bone marrow processing. Transfus Sci 1991; 12: 183–7
   PubMedGoogle Scholar
• Lasky L. C., Smith J., Fautsch S., et al. Development and analysis of a fully automated marrow processing technique using the Fenwal CS3000. Plasma Ther. 1985; 7: 424
   Google Scholar
• Axeman E., Cullis H., Sacher R., et al (1990) Automated isolation of mononuclear cells using the Fenwal CS3000 blood cell separator. Bone marrowing purging and processing, proceedings of the second international symposium on bone marrow purging and processing. 1990, S. R. Gross, A. Gee. Alan R. Liss, New York, 85–379
   Google Scholar
• Hillyer C. D., Tiegerman KO, Berkman E. M. Density gradient separation of peripheral blood stem cells: comparison of an automated cell processing device and manual methods. Transfusion 1990; 30: 824–7
   PubMedGoogle Scholar
• Pierelli L., Menichella G., Serafini R., et al. Autologous bone marrow processing for autotransplantation using an automated cell processor and a semiautomated procedure. Bone Marrow Transplant. 1991; 7: 355–61
   PubMed Web of Science ®Google Scholar
• Janssen W. E., Lee C., Smilee R., et al. Use of the Terumo SteriCell for the processing of bone marrow and peripheral blood stem cells. J Hematother. 1992; 1: 349–59
   PubMedGoogle Scholar
• Yeager A. M., Kaizer H., Santos G. W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia using ex vivo marrow treatment with hydro-peroxycyclophosphamide. N Engl J Med 1986; 315: 141–7
   PubMed Web of Science ®Google Scholar
• Rowley S. D., Jones R. J., Piantadosi S., et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989; 74: 501–6
   PubMed Web of Science ®Google Scholar
• McMillan A. K., Goldstone A. H., Linch D. C., et al. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 1990; 76: 480–8
   PubMed Web of Science ®Google Scholar
• Linker C. A., Ries C. A., Damon L. E., et al. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311–8
   PubMed Web of Science ®Google Scholar
• Douay L., Gorin N. C., Laporte J-P, et al. ASTA Z7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows. Invest New Drugs. 1984; 2: 187–90
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Ramakrishnan S, Houston L. L. Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. Cancer Res 1985; 45: 69–75
   PubMed Web of Science ®Google Scholar
• Gorin N. C., Labopin M., Meloni G., et al. Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia. 1991; 5: 896–904
   PubMed Web of Science ®Google Scholar
• Miller C. B., Zehnbauer B A, Piantadosi S., et al. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood 1991; 78: 1125–31
   PubMed Web of Science ®Google Scholar
• DeFabritiis P., Bregni M., Lipton J., et al. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 1985; 65: 1064–70
   PubMedGoogle Scholar
• Santos G., Colvin O. Pharmacologic purging of bone marrow with reference to autografting. Clin Hematol 1986; 15: 67–83
   PubMedGoogle Scholar
• DeFabritiis P., Pulsoni A., Sandrelli F., et al. Efficacy of a combined treatment with ASTA-Z 7654 and VP16–214 in vitro in eradicating clonogenic tumor cells from human bone marrow. Bone Marrow Transplant. 1987; 2: 287–98
   PubMedGoogle Scholar
• Gulati S. C., Atzpodien J., Langleben A., et al. Comparative regimens for the ex vivo chemopurification of B cell lymphoma-contaminated marrow. Acta Haematol 1988; 80: 65–70
   PubMed Web of Science ®Google Scholar
• Shimazaki C., Gulati S. C., Atzpodien J., et al. Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16–213. Acta Haematol 1988; 80: 17–22
   PubMedGoogle Scholar
• Gulati S. C., Kwon J-H, Kushner B., et al. In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide. Cancer Invest 1989; 7: 417–22
   PubMedGoogle Scholar
• Shpall E. J., Bast R. C., Joines W., et al. Immunopharmacologic bone marrow purging in metastatic breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Proc Am Soc Clin Oncol. 1990; 9: 9
   Google Scholar
• Reece D. E., Barnett M. J., Connors J. M., et al. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Bone Marrow Transplant 1993; 11: 139–46
   PubMed Web of Science ®Google Scholar
• Rowley S. C., Miller C. B., Piantadosi S., et al. Phase I study of combination drug purging for autologous bone marrow transplantation. J Clin Oncol. 1991; 9: 2210–18
   PubMed Web of Science ®Google Scholar
• Auber M. L., Horwitz L. J., Blaaub A., et al. Evaluation of drugs for elimination of leukemic cells from the bone marrow of patients with acute leukemia. Blood 1988; 71: 166
   PubMedGoogle Scholar
• Berdel W. E. Membrane-interactive lipids as experimental anticancer drugs. Br J Cancer 1991; 64: 208–10
   PubMedGoogle Scholar
• Noseda A., Berens M. E., White J. G., et al. In vitro antiproliferative activity of combinations of either lipid analogues and DNA-interactive agents against human tumor cells. Cancer Res 1988; 48: 1788–91
   PubMedGoogle Scholar
• Vogler W. R., Berdel W. E., Olson A. C., et al. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid. Blood 1992; 80: 1423–9
   PubMed Web of Science ®Google Scholar
• Andreesen R., Modolell M., Oepke GHF, et al. Temperature dependence of leukemic cell destruction by alkyl-lysophospholipids (NSC 324368). Exp Hematol 1983; 11: 564–70
   PubMedGoogle Scholar
• Okamoto S., Olson A. C., Berdel W. E., et al. Purging of acute myeloid leukemic cells by ether lipids and hyperthermia. Blood 1988; 72: 1777–83
   PubMed Web of Science ®Google Scholar
• Becton D. L., Bryles P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res 1988; 48: 7189–92
   PubMed Web of Science ®Google Scholar
• Blatt J., Taylor SR, Kontoghiorghes G. J. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 1989; 49: 2925–7
   PubMed Web of Science ®Google Scholar
• Skala J. P., Rogers PCJ, Chan K-W, et al. Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma. Advances in bone marrow purging and processing. Wiley-Liss, New York 1992; 8–71
   Google Scholar
• Treleaven J. G., Ugelstad J., Philip T., et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet. 1984; 1: 70–3
   PubMed Web of Science ®Google Scholar
• Greenberg P. L., Baker S., Link M., et al. Immunologic selection of hemopoietic precursor cells utilizing antibody-mediated plate binding (“panning”). Blood 1985; 65: 190–7
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Bensiger W. I., Kalamasz D., et al. Elimination of Daudi lymphoblasts from human bone marrow using avidin-biotin immunoadsorption. Blood 1986; 67: 509–15
   PubMedGoogle Scholar
• Kemshead J. T., Heath L., Gibson F. M., et al. Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 1986; 54: 771–8
   PubMedGoogle Scholar
• Reynolds C. P., Seeger R. C., Vo D. D., et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46: 5882–6
   PubMed Web of Science ®Google Scholar
• Gee A. P., Boyle MDP. Purging tumor cells from bone marrow by use of antibody and complement: a crucial appraisal. J Nad Cancer Inst 1988; 80: 154–9
   PubMedGoogle Scholar
• Kvalheim G., Sorensen O., Fodstadt O., et al. Immunomagnetic removal of B lymphoma cells from human bone marrow: a procedure for clinical use. Bone Marrow Transplant. 1988; 3: 31–41
   PubMed Web of Science ®Google Scholar
• Berthold F., Schumacher R., Schneider A., et al. Removal of neuroblastoma cells from bone marrow by a direct monoclonal antibody rosetting technique. Bone Marrow Transplant. 1989; 4: 273–8
   PubMedGoogle Scholar
• Kulkami S. S., Wang Z., Spitzer G., et al. Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement. Blood 1989; 74: 2244–51
   PubMedGoogle Scholar
• Slaper-Cortenbach IGM, Admiraal L. G., van Leeuwen E. F., et al. Effective purging of bone marrow by a combination of immunorosette depletion and complement lysis. Exp Hematol 1990; 18: 49–54
   PubMed Web of Science ®Google Scholar
• Tondini C., Pap S. A., Hayes D. F., et al. Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow. Cancer Res 1990; 50: 1170–5
   PubMed Web of Science ®Google Scholar
• Vredenburgh J. J., Ball E. D. Elimination of small cell carcinoma of the lung from human bone marrow by monoclonal antibodies and immunomagnetic beads. Cancer Res 1990; 50: 7216–20
   PubMedGoogle Scholar
• Anderson K. C., Barut B. A., Ritz J., et al. Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood 1991; 77: 712–20
   PubMed Web of Science ®Google Scholar
• Lemoli R. M., Gasparetto C., Scheinberg D. A., et al. Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination. Blood 1991; 77: 1829–36
   PubMed Web of Science ®Google Scholar
• Shpall E. J., Bast RC, Jr, Joines W. T., et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant. 1991; 7: 145–51
   PubMed Web of Science ®Google Scholar
• Rhodes EGH, Baker P. K., Rhodes J. M., et al. Peanut agglutinin in combination with CD19 monoclonal antibody has potential as a purging agent in myeloma. Exp Hematol 1991; 19: 833–7
   PubMed Web of Science ®Google Scholar
• Gee A., Moss T., Mansour V., et al. Large-scale immunomagnetic separation system for the removal of tumor cells from bone marrow. Advances in bone marrow purging and processing. Wiley-Liss, New York 1992; 818–87
   Google Scholar
• Morishima Y., Miyamura K., Kojima S., et al. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant 1993; 11: 255–9
   PubMedGoogle Scholar
• Treichel R. S. Autologous bone marrow transplantation for leukemia: monoclonal antibody-mediated purging of multidrug-resistant leukemia. LeukRes 1993; 17: 491–9
   Google Scholar
• Berenson R. J., Bensinger WI, Kalamasz D. Positive selection of viable cell populations using avidin-biotin immunoadsorption. J Immunol Methods 1986; 91: 11–9
   PubMed Web of Science ®Google Scholar
• Sieber F., Spivak JL, Sutcliff A. M. Selective killing of leukemic cells by merocyanine-540 mediated photosensitization. Proc Natl Acad Sci USA 1984; 81: 7584–7
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Gulati SC, Clarkson B. D. Comparison of the cytotoxic effects of merocyanine-540 on leukemic cells and normal human bone marrow. Cancer Res 1986; 46: 4892–5
   PubMedGoogle Scholar
• Atzpodien J., Gulati S. C., Strife A., et al. Photoradiation models for the clinical ex vivo treatment of autologous bone marrow grafts. Blood 1987; 70: 484–9
   PubMed Web of Science ®Google Scholar
• Gulati S., Atzpodien J., Lemoli R. M., et al. Photoradiation methods for purging autologous bone marrow grafts. Bone marrow purging and processing. Alan R. Liss, New York 1990; 87–102
   Google Scholar
• Lemoli R. M., Igarashi T., Knizewski M., et al. Dye-mediated photolysis is capable of eliminating drug-resistant (MDR+) tumor cells. Blood 1993; 81: 793–800
   PubMed Web of Science ®Google Scholar
• Dexter T. M., Allen TD, Lajtha L. G. Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 1977; 91: 335–44
   PubMed Web of Science ®Google Scholar
• Gartner S., Kaplan H. S. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 1980; 77: 4756–9
   PubMed Web of Science ®Google Scholar
• Coulombel L., Kalousek D. K., Eaves C. J., et al. Long term marrow culture reveals chromosoma-Uy normal haemopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med 1983; 308: 1493–8
   PubMed Web of Science ®Google Scholar
• Coulombel I., Eaves C., Kalousek D., et al. Long term marrow culture of cells from patients with myelogenous leukemia: selection in favor of normal phenotypes in some but not all cases. J Clin Invest 1985; 75: 961–9
   PubMed Web of Science ®Google Scholar
• Chang J., Morgenstem G., Deakin D., et al. Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture. Lancet. 1986; 1: 294–5
   PubMed Web of Science ®Google Scholar
• Barnett M. J., Eaves C. J., Phillips G. L., et al. Successful autografting in chronic myeloid leukaemia after maintenance of marrow in culture. Bone Marrow Transplant. 1989; 4: 345–51
   PubMed Web of Science ®Google Scholar
• Chang J., Morgenstem G. R., Coutinho L. H., et al. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update. Bone Marrow Transplant. 1989; 4: 5–9
   PubMed Web of Science ®Google Scholar
• Visani G., Lemoli R. M., Dinota A., et al. Evidence that long-term bone marrow culture of patients with multiple myeloma favors normal hemopoietic proliferation. Transplantation 1989; 48: 1026–31
   PubMed Web of Science ®Google Scholar
• Schiro R., Coutinho L. H., Will A., et al. Growth of normal versus leukemia bone marrow cells in long term culture from acute lymphoblastic and myeloblastic leukemias. Blut 1990; 67: 267–70
   Google Scholar
• Firkin F. C., Birner R, Farag S. Differential action of diffusible molecules in long-term marrow culture on proliferation of leukaemic and normal haemopoietic cells. Br J Haematol 1993; 84: 8–15
   PubMed Web of Science ®Google Scholar
• Da W. M., Douay L., Barbu V., et al. Serum-free liquid marrow culture in patients with acute lymphoblastic leukaemia: a potential application to purge marrow for autologous transplantation. Br J Haematol 1991; 78: 42–7
   PubMedGoogle Scholar
• Szczylik C., Skorski T., Nicolaides N. C., et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253: 562–5
   PubMed Web of Science ®Google Scholar
• Martiat P., Lewalle P., Taj A. S., et al. Retrovirally transduced antisense sequences stably suppress P210BCR-ABLexpression and inhibit the proliferation of BCR/ABL-containing cell lines. Blood 1993; 81: 502–9
   PubMed Web of Science ®Google Scholar
• McGlave P., Mamus S., Vilen B., et al. Effect of recombinant gamma interferon on chronic myelogenous leukemia bone marrow progenitors. Exp Hematol 1987; 15: 331–5
   PubMed Web of Science ®Google Scholar
• Becker M., Fabrega S., Belloc F., et al. Preliminary report. Interferon gamma is effective for BM purging in a patient with CML. Bone Marrow Transplant 1993; 12: 155–8
   PubMed Web of Science ®Google Scholar
• Gulati S. C., Shimazaki C., Lemoli R. M., et al. Ex vivo treatment of myeloma cells by 4-HC, VP-16, LAK cells and antibodies. Eur J Haematol Suppl 1989; 43: 164–72, 51
   Google Scholar
• Civin C. I., Strauss L. C., Broval C., et al. Antigenic analysis of hematopoiesis. HI. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KGla cells. J Immunol 1984; 133: 157
   PubMed Web of Science ®Google Scholar
• Tindle R. W., Nichols RAB, Chan L., et al. A novel monoclonal antibody B1–3C5 recognizes myeloblasts and non T, non B lymphoblasts in acute leukemias and CGL blast crisis, reacts with immature cells in normal marrow. Leuk Res. 1985; 9: 1
   PubMed Web of Science ®Google Scholar
• Andrews R. G., Singer JW, Bernstein E. D. Monoclonal antibody 12–8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986; 67: 842–5
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Andrews R. G., Bensinger W. I., et al. Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951
   PubMed Web of Science ®Google Scholar
• Andrews R. G., Bryant E. M., Bartelmez S. H., et al. CD34+ marrow cells, devoid of T and B lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated allogeneic baboons. Blood 1992; 80: 1693–1701
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Bensinger W. I., Hill R. S., et al. Engraftment after infusion of CD34+marrow cells in patients with breast cancer of neuroblastoma. Blood 1991; 77: 1717–22
   PubMed Web of Science ®Google Scholar
• Fina L., Molgaard H. V., Robertson D., et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417–26
   PubMed Web of Science ®Google Scholar
• Hurwitz C. A., Loken M. R., Graham M. I., et al. Asynchronous antigen expression in B lineage acute lymphoblastic leukemia. Blood 1988; 72: 299–307
   PubMed Web of Science ®Google Scholar
• Vaughan W. P., Civin C. I., Weisenburger D. D., et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34. Leukemia 1988, (My 10): 661–6
   PubMedGoogle Scholar
• Borowitz M. J., Shuster J. J., Civin C. I., et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group Study. J Clin Oncol. 1990; 8: 1389–98
   PubMed Web of Science ®Google Scholar
• Civin C. I. Human monomyeloid cell membrane antigens. Exp Hematol 1990; 18: 461–7
   PubMed Web of Science ®Google Scholar
• Geller R., Zuharak M., Burke P. J., et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukemia: the significance of the stem-cell glycoprotein CD34 (my 10). Br J Haematol 1990; 76: 340–7
   PubMed Web of Science ®Google Scholar
• Berenson R. J., Bensinger W. I., Kalamasz D., et al. Transplantation of stem cells enriched by immunoadsorption. Advances in bone marrow purging and processing. Wiley-Liss, New York 1992; 59–449
   Google Scholar
• Okarma T., Lebkowski J., Schain L., et al. The AIS Cellecton a new technology for stem cell purification. In. Advances in bone marrow purging and processing. Wiley-Liss, New York 1992; 487–504
   Google Scholar
• Civin C. I. Identification and positive selection of human progenitor/stem cells for bone marrow transplantation. Advances in bone marrow purging and processing. Wiley-Liss, New York 1992; 73–461
   Google Scholar
• Leary A. G., Ikebuchi K., Hirai Y., et al. Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-la. Blood 1988; 71: 1759–63
   PubMed Web of Science ®Google Scholar
• Bernstein I. D., Andrews RG, Zsebo K. M. Recombinant human stem cell factor enhances the formation of colonies by CD34+and CD34+in-cells, and the generation of colony-forming cell progeny from CD34+lin-cells cultured with interleukin-3, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor. Blood 1991; 77: 2316–21
   PubMed Web of Science ®Google Scholar
• Bodine D. M., Crosier PS, Clark S. C. Effects of hematopoietic growth factors on the survival of primitive stem cells in liquid suspension culture. Blood 1991; 78: 914–20
   PubMed Web of Science ®Google Scholar
• Schneider J. G., Crown J., Shapiro F., et al. Ex vivo cytokine expansion of CD34-positive hematopoietic progenitors in bone marrow (BM). Blood 1992; 80: 268
   Google Scholar
• Tsuji K., Lyman S. D., Sudo T., et al. Enhancement of murine hematopoiesis by synergistic interactions between steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 1992; 79: 2855–60
   PubMed Web of Science ®Google Scholar
• Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993; 81: 2844–53
   PubMed Web of Science ®Google Scholar
• Lovelock J. E., Bishop MWH. Prevention of freezing damage to living cells by dimethyl sulphoxide. Nature (London) 1959; 183: 1394–5
   PubMed Web of Science ®Google Scholar
• Karow AM, Jr, Webb W. R. Tissue freezing. A theory for injury and survival. Cryobiology 1965; 2: 99–108
   PubMedGoogle Scholar
• Bouroncle B. A. Preservation of human normal and leukemic cells with dimethyl sulfoxide at -80°C. Cryobiology 1967; 3: 445–55
   PubMed Web of Science ®Google Scholar
• Takahashi T., Bross J. B., Shaber R. E., et al. Effect of cryoprotectants on the viability and function of unfrozen human polymorphonuclear cells. Cryobiology 1985; 22: 336–50
   PubMedGoogle Scholar
• Rowley S. D., Anderson G. L. Effect of DMSO exposure without cryopreservation on hematopoietic progenitor cells. Bone Marrow Transplant 1993; 11: 389–93
   PubMed Web of Science ®Google Scholar
• Goodman J. W., Hodgson G. S. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702–14
   PubMed Web of Science ®Google Scholar
• Reiffers J., Bernard P., David B., et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. Exp Hematol 1986; 14: 312–5
   PubMed Web of Science ®Google Scholar
• Fermand J-P, Levy Y., Gerota J., et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cell autologous graft. Blood 1989; 73: 20–3
   PubMed Web of Science ®Google Scholar
• Henon P. R., Butturini A, Gale R. P. Blood-derived haematopoietic cell transplants: blood to blood%. Lancet 1991; 337: 961–3
   PubMedGoogle Scholar
• Henon P. R., Liang H., Beck-Wirth G., et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant. 1992; 9: 285–91
   PubMed Web of Science ®Google Scholar
• Bensinger W., Singer J., Appelbaum F., et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993; 81: 3158–63
   PubMed Web of Science ®Google Scholar
• Kessinger A. Utilization of peripheral blood stem cells in autotransplantation. Autol Bone Marrow Transplant. 1993; 7: 535–45
   Google Scholar
• Schwartzberg L., Birch R., Blanco R., et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369–74
   PubMed Web of Science ®Google Scholar
• Korbling M. Some principles of blood stem cell transplantation. Transfus Sci 1993; 14: 61–4
   PubMedGoogle Scholar
• Craig JIO, Anthony R. S., Stewart A., et al. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 1993; 85: 210–2
   PubMed Web of Science ®Google Scholar
• Liu K-Y, Akashi K., Harada M., et al. Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 1993; 84: 31–8
   PubMed Web of Science ®Google Scholar
• Socinski M. A., Elias A., Schnipper L., et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet. 1988; 1: 1194–8
   PubMed Web of Science ®Google Scholar
• Chao N. J., Schriber J. R., Grimes K., et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–5
   PubMed Web of Science ®Google Scholar
• Peters W. P., Rosner G., Ross M., et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSD) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–19
   PubMed Web of Science ®Google Scholar
• Comenzo R. L., Malachowski M. E., Miller K. B., et al. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion 1992; 32: 729–31
   PubMed Web of Science ®Google Scholar
• Malachowski M. E., Comenzo R. L., Hillyer C. D., et al. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion 1992; 32: 732–5
   PubMed Web of Science ®Google Scholar
• Korbling M., Branham C. Quality control in stem cell processing for autotransplantation. Transfus Sci 1993; 14: 101
   PubMedGoogle Scholar
• Zingsem J., Zeiler T., Zimmermann R., et al. Selective enrichment of hematopoietic progenitor cells from peripheral blood. Transfus Sci 1993; 14: 75–77
   Google Scholar
• Sharp J. G., Kessinger M. A., Pirruccello S. J., et al (1991) Frequency of detection of suspected lymphoma cells in peripheral blood stem cell collections. Autologous bone marrow transplantation. Proceedings of the fifth international symposium. 1991, K. A. Dicke, J. O. Armitage, M. J. Dicke-Evinger. University of Nebraska Medical Center Press, Omaha, 801–10
   Google Scholar
• Polli E. E. The role of haematopoietic growth factors in bone marrow transplantation. Acta Haematol 1991; 86: 155
   PubMedGoogle Scholar
• Devereux S., Linch D. C., Gribben J. G., et al. GM-CSF accelerates neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant. 1989; 4: 49
   Web of Science ®Google Scholar
• Blazar B. R., Kersey J. H., McGlave P. B., et al. In vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989; 73: 849
   PubMed Web of Science ®Google Scholar
• Neben S., Marcus K, Mauch P. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. Blood 1993; 81: 1960
   PubMed Web of Science ®Google Scholar
• Henon R., Liang H., Beck-Wirth G., et al. Granulocyte-macrophage colony stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet. 1989; 9: 285
   Google Scholar
• Siena S., Bregni M., Brando B., et al. Row cytometry to estimate circulating hematopoietic progenitors for autologous transplantation: comparative analysis of different CD34 monoclonal antibodies. Haematologica 1991; 76: 330
   PubMed Web of Science ®Google Scholar
• Ravagnani F., Siena S., Bregni M., et al. Large-scale collection of circulating hematopoietic progenitors in cancer patients treated with high-dose cyclophosphamide and recombinant human GM-CSF. Eur J Cancer 1990; 26: 562
   PubMed Web of Science ®Google Scholar
• Bregni M., Mgni M., Siena S., et al. Human peripheral blood hematopoietic progenitors are optimal targets of retroviral-mediated gene transfer. Blood 1992; 80: 1418
   PubMed Web of Science ®Google Scholar
• Clark S. C., Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229
   PubMed Web of Science ®Google Scholar
• Ross W., Peeke J. Radioprotection conferred by dextran sulfate given before irradiation in mice. Exp Hematol 1986; 14: 147
   PubMed Web of Science ®Google Scholar
• Juttner C. A., To L. B., Hay lock DN, et al. Autologous blood stem cell transplantation. Transplant Proc 1989; 21: 2929
   PubMed Web of Science ®Google Scholar
• Giani A., Bregni M., Siena S., et al. Rapid and complete hematopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemoradiotherapy%. Hematol Oncol 1989; 7: 139
   PubMedGoogle Scholar
• Juttner C. A., To L. B., Haylock D. N., et al. Peripheral blood stem cell selection, collection, and auto-transplantation. Prog Clin Biol Res 1990; 333: 447
   PubMedGoogle Scholar
• Siena S., Bregni M., Brando B., et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905
   PubMed Web of Science ®Google Scholar
• Myers S. E., Williams SF, Geller R. B. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplantation after high-dose chemotherapy: clinical results in patients with contaminated or hypocellular bone marrow. J Hematother. 1992; 1: 27
   PubMedGoogle Scholar
• Schwartzberg L. S., Birch R., Hazelton B., et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother. 1992; 1: 317
   PubMedGoogle Scholar
• Petros W. P., Peters W. P. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993; 20: 94
   PubMedGoogle Scholar
• Gianni A. M., Bregni M., Siena S., et al. Recombinant human granulocyte-macrophage colony-stimulating. factor reduces hematopoietic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol. 1990; 8: 768
   PubMed Web of Science ®Google Scholar
• Shea T. C., Mason J. R., Storniolo A. M., et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992; 10: 464
   PubMed Web of Science ®Google Scholar
• Cole L. Hematopoietic restoration in lethally x-irradiated mice injected with peritoneal exudates. Am J Physiol 1963; 204: 265
   PubMedGoogle Scholar
• Micklem H. S., Anderson N, Ross E. Limited potential of circulating haematopoietic stem cells. Nature (London) 1975; 256: 41
   PubMed Web of Science ®Google Scholar
• Tong J., Hoffman R., Siena S., et al. Characterization and qualification of primitive hematopoietic progenitor cells present in peripheral blood autografts. Exp. Hematol. 1994; 22: 1016–24
   PubMed Web of Science ®Google Scholar
• Srour E. F., Zanjani E. D., Brandt J. E., et al. Sustained human hematopoiesis in sheep transplanted in utero during early gestation with fractionated adult human bone marrow cells. Blood 1992; 79: 1404
   PubMed Web of Science ®Google Scholar
• Srour E. F., Brandt J. E., Briddell R. A., et al. Long-term generation and expansion of human primitive hematopoietic progenitor cells in vitro. Blood 1993; 81: 661
   PubMed Web of Science ®Google Scholar
• Srour E. F., Brandt J. E., Briddell R. A., et al. Human CD34+ HLA-DR-bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells 1991; 17: 287
   PubMedGoogle Scholar
• Bender J. G., To L. B., Williams S., et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother. 1992; 1: 329
   PubMedGoogle Scholar
• To L. B., Haylock D. N., Dyson P. G., et al. An unusual pattern of hemopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6: 109
   PubMed Web of Science ®Google Scholar
• Serke S., Sauberiich S., Huhn D. Multiparameter flow-cytometrical quantitation of circulating CD34(+)-cells: correlation to the quantitation of circulating haemopoietic progenitor cells by in vitro colony-assay. Br J Haematol 1991; 77: 453
   PubMed Web of Science ®Google Scholar
• Fritch G., Emminger W., Buchinger P., et al. CD34-positive cell proportions in peripheral blood correlate with colony-forming capacity. Exp Hematol 1991; 19: 1079
   PubMedGoogle Scholar
• Demitri G. D. Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy%. Blood 1993; 82(8)2278–80
   PubMedGoogle Scholar
• Gerhartz H. H., Engelhard M., Meusers P., et al. Randomized, double-blind, placebo-controlled, phase UI study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant nonHodgkin's lymphomas. Blood 1993; 82(8)2329–39
   PubMed Web of Science ®Google Scholar
• Siena S., Bregni M., Bonsi L., et al. Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. Exp Hematol 1993; 21: 1583–90
   PubMed Web of Science ®Google Scholar
• Neidhart J. A. Hematopoietic cytokins. Current use in cancer therapy. Cancer 1993; 72(11)3381–6
   PubMedGoogle Scholar
• Appelbaum F. R. The use of colony stimulating factors in marrow transplantation. Cancer 1993; 72(11)3387–92
   PubMedGoogle Scholar
• Henon P. R., Becker M. Cytokine enhancement of peripheral blood stem cells. Stem Cells. 1993; 2: 65–71
   Google Scholar
• Anderson W. F. Prospects for human gene therapy. Science 1984; 226: 401–9
   PubMed Web of Science ®Google Scholar
• Anderson W. F. Human gene therapy. Science 1992; 256: 808–13
   PubMed Web of Science ®Google Scholar
• Apperley J. F. Gene therapy: current status and future directions. Br J Haematol 1990; 75: 55–148
   Google Scholar
• Blaese R. M. Treatment of SCID due to adenosine deaminase deficiency with CD34+ selected autologous peripheral blood cells transduced with a human ADA gene. Hum Gene Ther. 1993; 5: 521–7
   Google Scholar
• Bordignon C. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther. 1993; 4: 513–20
   Google Scholar
• Brenner M., Mirro J, Jr, Hurwitz C., et al. Autologous bone marrow transplant for children with AML in first remission: use of marker genes to investigate the biology of marrow reconstitu-tion and the mechanism of relapse. Hum Gene Ther. 1991; 2: 137–59
   PubMed Web of Science ®Google Scholar
• Corey C. A., DeSilva A. D., Holland C. A., et al. Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 1990; 75: 337–43
   PubMed Web of Science ®Google Scholar
• Cornetta K. Safety aspects of human gene therapy. Br J Haematol 1992; 80: 421–6
   PubMed Web of Science ®Google Scholar
• Cometta K., Moen R. C., Culver K., et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther. 1990; 1: 13–26
   Google Scholar
• Cometta K., Tricot G., Broun E. R., et al. Clinical protocols: retroviral mediated gene transfer of bone marrow cell during autologous bone marrow transplantation for acute leukemia. Hum Gene Ther. 1992; 3: 305–18
   PubMedGoogle Scholar
• Davis B. R., Schwartz D. H., Marx J. C., et al. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 1991; 65: 1985–90
   PubMed Web of Science ®Google Scholar
• Donahue R. E., Kessler S. W., Bodine D., et al. Helper virus induction T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 35–1125
   Google Scholar
• Dunbar C. E. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia or metastatic breast cancer. Hum Gene Ther. 1993; 4: 205–22
   PubMedGoogle Scholar
• Economou J. S. Treatment of patient with metastatic melanoma and renal cell carcinoma using in vitro expanded and genetically engineered bulk, CD8+ and/or CD4+ tumor infiltrating lymphocytes and bulk, CD8+ and/or CD4+ peripheral blood leukocytes in combination with recombinant interleukin-2 alone or with recombinant interleukin-2 and recombinant alpha interferon. Hum Gene Ther. 1992; 3: 411–30
   PubMedGoogle Scholar
• Etkin M., Filaccio M, Ellerson D. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Hum Gene Ther. 1992; 3: 137–45
   PubMed Web of Science ®Google Scholar
• Favrot M. C., Philip T. Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. Hum Gene Ther. 1992; 3: 533–42
   PubMedGoogle Scholar
• Folks T. M., Kessler S. W., Orenstein J. M., et al. Infection and replication of HTV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242: 919–22
   PubMed Web of Science ®Google Scholar
• Friedmann T. Progress toward human gene therapy. Science 1989; 244: 1275–8
   PubMed Web of Science ®Google Scholar
• Hobbs J. R. Displacement bone marrow transplantation for some inborn errors. J Inherited Metab Dis 1990; 13: 572–95
   PubMedGoogle Scholar
• Hoogerbrugge P. M., Vossen JMJJ, van Beusechem V. W., et al. Treatment of patients with severe combined immunodeficiency due to ADA deficiency by autologous transplantation of genetically modified bone marrow cells. Hum Gene Ther. 1992; 3: 553–8
   PubMedGoogle Scholar
• Komeluk R. G., MacLeod H. L., McKeithan T. W., et al. A chromosome 19 clone from a translocation breakpoint shows close linkage and linkage disequilibrium with myotonic dystrophy. Genomics. 1989; 4: 146–51
   PubMedGoogle Scholar
• Kotin R. M., Siniscaloco M., Samulski R. J., et al. Site-specific integration by adeno-associated vims. ProcNatl Acad Sci USA 1990; 87: 2211–5
   PubMed Web of Science ®Google Scholar
• Krauss J. C. Hematopoietic stem cell gene replacement therapy. Biochim Biophys Acta 1992; 1114: 193–207
   PubMedGoogle Scholar
• Lotze M. T. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes. Hum Gene Ther. 1992; 3: 167–77
   PubMedGoogle Scholar
• Mann R., Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153–9
   PubMed Web of Science ®Google Scholar
• McKeithan T. W., Rowley J. D., Shows T. B., et al. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1987; 84: 9257–60
   PubMed Web of Science ®Google Scholar
• Mc Lachlin, Jr, Eglitis M. A., Ueda K., et al. Expression of a human complementary DNA for the multidrug resistance gene in murine hematopoietic precursor cells with the use of retroviral gene transfer. J Natl Cancer Inst 1990; 82: 1260–3
   PubMedGoogle Scholar
• Miller A. D. Retrovirus packaging cells. Hum Gene Ther. 1990; 1: 5–14
   PubMed Web of Science ®Google Scholar
• Miller A. D. Human gene therapy comes of age. Nature (London) 1992; 357: 455–60
   PubMed Web of Science ®Google Scholar
• Mulligan R. C. The basic science of gene therapy. Science 1993; 260: 926–32
   PubMed Web of Science ®Google Scholar
• Nabel G. J., Chang A, Nabel E. G. Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther. 1992; 3: 399–410
   PubMed Web of Science ®Google Scholar
• Nahreini P., Woody M. J., Zhen Zhou S., et al. Versatile adeno-associated virus 2-based vectors for constructing recombinant virions. Gene 1993; 124: 257–62
   PubMedGoogle Scholar
• Osanto S. Immunization with interleukin-2 transfected melanoma cells. Hum Gene Ther. 1993; 4: 323–30
   PubMedGoogle Scholar
• Pastan I., Gottesman M. M. Multidrug resistance. Annu Rev Med 1991; 42: 277–86
   PubMed Web of Science ®Google Scholar
• Riddell S. R., Greenberg P. D., Overell R. W., et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HTV-specific T cells for HTV seropositive patients undergoing allogeneic bone marrow transplant. Hum Gene Ther 1992; 3: 319–38
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin 2. Hum Gene Ther 1992a; 3: 75–90
   PubMedGoogle Scholar
• Rosenberg S. A. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor. Hum Gene Ther. 1992; 3: 57–73
   PubMedGoogle Scholar
• Rosenberg S. A., Aebersold P. M., Cornetta K., et al. Gene transfer into humans – immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–8
   PubMed Web of Science ®Google Scholar
• Rosenfeld M. A., Yoshimura K., Trapnell B. C., et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143–55
   PubMed Web of Science ®Google Scholar
• Sorrentino B. P., Brandt S. J., Bodine D., et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• Stanley S. K., Kessler S. W., Justement J. S., et al. CD34+ bone marrow cells are infected with HTV in a subset of seropositive individuals. J Immunol 1992; 149: 689–97
   PubMed Web of Science ®Google Scholar
• Steinberg H. N., Crumpacker C. S., Chatis P. A. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol 1991; 65: 1765–9
   PubMed Web of Science ®Google Scholar
• Watanabe S., Temin H. M. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol Cell Biol. 1983; 3: 2241–9
   PubMed Web of Science ®Google Scholar
• Williams D. A. Expression of introduced genetic sequences in hematopoietic cells following retroviral-mediated gene transfer. Hum Gene Ther. 1990; 1: 229–39
   PubMed Web of Science ®Google Scholar
• Williams D. A., Hsieh K., DeSilva A., et al. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp. Med 1987; 166: 210–8
   PubMed Web of Science ®Google Scholar
• Zauli G., Re M. C., Davis B., et al. Impaired in vitro growth of purified (CD34+) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals. Blood 1992; 79: 2680–7
   PubMedGoogle Scholar
• Zhen S. Zhou, Broxmeyer H. E., Cooper S., et al. Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol, (in press)
   Google Scholar
• International Bone Marrow Transplant Registry. Personal communication
   Google Scholar
• Cornetta K., Hoffman R. Manuscript in preparation
   Google Scholar